mp-099 - mp-099 - Medical Policies
Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening
Policy Number: MP-099
Effective November 1, 2017
This policy is no longer in effect
Process per contract benefits
Policy #: 099
Latest Review Date: November 2015
Category: Laboratory Policy Grade: B
Description of Procedure or Service:
Detection of genetic abnormalities associated with colorectal cancer in stool samples has been proposed as a screening test for colorectal cancer. This technology is another potential alternative to currently available screening approaches such as fecal occult blood testing, fecal immunochemical testing (FIT), or colonoscopy.
Several cellular genetic alterations have been associated with colorectal cancer (CRC). In the proposed multistep model of carcinogenesis, the tumor suppressor gene p53 and the proto-oncogene K-ras are most frequently altered. Mutations in APC (adenomatous polyposis coli) genes and epigenetic markers (e.g., hypermethylation of specific genes) have also been detected. Colorectal cancer is also associated with DNA replication errors in microsatellite sequences (termed microsatellite instability) in patients with Lynch syndrome (formerly known as hereditary nonpolyposis colorectal cancer) and in subgroups of patients with sporadic colon carcinoma. Tumor-associated gene mutations and epigenetic markers can be detected in exfoliated intestinal cells in stool specimens. Because cancer cells are shed into stool, tests have been developed that detect these genetic alterations in the DNA from shed colorectal cancer cells isolated from stool samples.
Effective November 1, 2017 this policy is no longer in effect. Process per contract benefits.
Effective for dates of service prior to November 1, 2017:
DNA analysis of stool samples to screen for colorectal cancer is considered not medically necessary and investigational.
This policy is regularly updated with searches of the MEDLINE database. The most recent literature search was performed through October 1, 2015.
The important outcome of interest in cancer screening is a reduction in the mortality and morbidity due to cancer. This is ideally determined with randomized clinical trials. However, for colon cancer screening, many of the recommended tests have not been evaluated with clinical trials. The efficacy of these tests is supported by numerous studies evaluating the diagnostic characteristics of the test for detecting cancer and cancer precursors along with a well-developed body of knowledge regarding the natural history of the progression of cancer precursors to cancer. Modelling studies have evaluated the robustness and quantity of health benefit of various screening tests when clinical trial evidence is lacking.
Lacking direct evidence of screening in reducing cancer mortality, the critical parameters in the evaluation of a screening test are the diagnostic performance characteristics (i.e., sensitivity, specificity, positive and negative predictive value) compared with a criterion standard, the proposed frequency of screening, and the follow-up management of test results. The diagnostic performance characteristics of the currently accepted screening options (i.e., fecal occult blood testing [FOBT], fecal immunochemical testing [FIT], flexible sigmoidoscopy, double contrast barium enema) have been established using colonoscopy as the criterion standard. Modelling studies and clinical trial evidence on some of the screening modalities have allowed some confidence on the effectiveness of currently recommended cancer screening modalities.
For patients at average to moderate risk for colorectal cancer, organizations such as the U.S. Preventive Services Task Force recommend several options for colon cancer screening Advocates of DNA testing of stool samples have hypothesized that the relative simplicity of collecting a stool sample might increase the overall compliance with screening recommendations, and the detection of cancer-associated DNA may be superior to current stool tests for the detection of cancer and cancer precursors.
There are no studies of stool DNA testing for screening of individuals at high risk of colorectal cancer.
Literature Review of FDA-Approved Cologuard
Preliminary studies of the test which was eventually evaluated in the large scale screening study by Imperiale et al were conducted by Ahlquist et al and Lidgard et al. This multitarget stool DNA test consists of quantitative measurements of molecular assays for aberrantly methylated BMP3 and NDRG4 promoter regions, mutant KRAS, β- actin, and hemoglobin in a logistic-regression algorithm. Since it includes a fecal immunochemical test (FIT) in its algorithm, it is actually a combined fecal DNA and FIT test. In a study of 252 patients with CRC, 133 patients with adenomas of 1 cm or larger and 293 subjects with normal colonoscopy, the test detected 85% of colon cancer cases and 54% of subjects with adenomas, with 90% specificity. Another smaller study of this same test showed a sensitivity of 87% for detecting CRC and 82% sensitivity for detecting adenomas.3 In the study by Lidgard et al of 1003 patients, there were 207 cases with CRC or advanced adenomas (>1 cm), and 796 control patients with no polyps or nonadvanced adenomas (<1 cm). In the case group, 93 subjects had CRC, 84 had advanced adenoma 1 cm or larger and 30 had sessile serrated adenoma 1 cm or larger. In the control group, 155 subjects had nonadvanced adenomas and 641 did not have any colonic lesions. Using a logistic regression algorithm that incorporates 11 markers into 1 regression score and a fixed specificity of 90%, the fecal DNA test identified 84 of 86 (98% sensitivity) CRCs and 41 of 73 (56% sensitivity) advanced adenoma cases. These preliminary studies all evaluated fecal DNA using pre-assembled samples of study subjects with and without cancer or colonic lesions. Diagnostic characteristics of tests evaluated in these types of study samples may be biased.
A large-scale evaluation of this test in a screening population was published in 2014 by Imperiale et al1 and compared the fecal DNA test with FIT in 12,000 asymptomatic persons at average risk for CRC. The results of this study supported the U.S. Food and Drug Administration (FDA) approval of this fecal DNA test (Cologuard™) in August 2014. All enrolled subjects were scheduled to undergo screening colonoscopy. Stool specimens were collected and tested no more than 90 days before the screening colonoscopy. Screening colonoscopy findings were considered the reference standard for determining the diagnostic characteristics of the fecal DNA test and FIT for detecting CRC and cancer precursors. In 9989 evaluable subjects, fecal DNA test sensitivity for cancer was 92.3% and 73.8% for FIT. For advanced precancerous lesion, fecal DNA test sensitivity was 42.4% and 23.8% for FIT. In analyses of specific types of lesions, sensitivity of the fecal DNA test did not vary by cancer stage or cancer location. Among patients with advanced precancerous lesions, the sensitivity of fecal DNA testing was higher for distal lesions than for proximal lesions. Fecal DNA test sensitivity increased as lesion size increased. The specificity of the fecal DNA test was lower than that of FIT. For identification of patients with insignificant lesions and negative colonoscopy, specificity of the fecal DNA test was 86.6% versus 94.9% for FIT. For identification of patients with negative colonoscopy, specificity of the fecal DNA test was 89.8% versus 96.4% for FIT.
Impact on Health Outcomes
There are no studies evaluating direct health outcomes of a screening program using Cologuard. In 2014, the Blue Cross Blue Shield Association Technology Evaluation Center evaluated fecal DNA analysis for CRC screening in a special report. The report found the Imperiale study to be of good quality but noted while fecal DNA testing had higher sensitivity than FIT for various types of colorectal lesions, these results represent the diagnostic characteristics of the fecal DNA test in a one-time cross sectional study. How these study results may translate to reduced colorectal mortality in a screening program are uncertain. The study of the diagnostic characteristics of a test for detecting cancer and cancer precursors does not establish efficacy for prevention of CRC. Effective screening for CRC requires a screening program with established screening intervals and appropriate follow-up for positive tests. Given what is known about relative efficacy of different screening strategies from the results of modelling studies, the fecal DNA test would produce equivalent or better outcomes than FIT if both were used annually. However, the fecal DNA test has a considerably higher false-positive rate and would therefore consume greater health care resources than FIT at this screening frequency. Formal modelling studies of the fecal DNA test are needed to estimate the efficacy of the test in preventing CRC and help determine the optimal strategy for its use.
Literature Review of Previously Marketed Tests
A 2004 study by Imperiale et al evaluated a test marketed as the PreGen-Plus™. This study was a prospective trial of 5486 enrolled subjects. The results of this study were the principal evidence used to support prior practice recommendations regarding fecal DNA cancer screening.
Subjects underwent fecal occult blood testing (FOBT), fecal DNA analysis using a precommercial version of the test, and colonoscopy, considered the criterion standard for this trial. Of the 5486 enrolled, 4404 completed all aspects of the study and, from this group, 2507 underwent comparative analysis. The subgroup was chosen by including all subjects who were found to have adenocarcinoma (n=31) and a random selection of subjects with adenomas, polyps, or normal findings. The sensitivity of fecal DNA analysis and FOBT for all cancers and adenomas with high-grade dysplasia was 40.8% versus 14.1%, respectively. Specificity in subjects with a negative finding on colonoscopy was 94.4% for fecal DNA and 95.3% for FOBT. This study is the first large study of fecal DNA testing in an asymptomatic average-risk population.
However, several problematic issues regarding the study were addressed in an editorial by Woolf, who urges caution in interpreting the results of the Imperiale et al study. For example, Woolf notes the wide confidence intervals around the sensitivity of fecal DNA, ranging from 35% to 68%, which preclude any firm estimates of the magnitude of benefit associated with fecal DNA testing.
Another previously marketed test, ColoSure™, has not been evaluated in a large screening study. Two studies allow calculation of the performance characteristics of the hypermethylated vimentin (hV) gene alone. In a study by Itzkowitz et al, separately assembled groups of patients with colorectal cancer (n=40) and patients with normal colonoscopy (n=122) were tested with hV. Sensitivity was 72% and specificity was 87%. In a second study by Itzkowitz et al, separately assembled groups of patients with colorectal cancer (n=82) and patients with normal colonoscopy (n=363) were tested with hV and a two-site DNA integrity assay. The purpose of the study was to calculate diagnostic performance characteristics of this combined test, but the results are also presented for hV alone. Using data-derived cut-off values, the sensitivity for cancer was 77% and the specificity was 83%. Other studies of hypermethylated vimentin using different assays have shown sensitivities of 38% and 41% for detecting colorectal cancer.
None of these studies is adequate to evaluate a screening test. The study samples are enriched with cancer cases that may not represent the prevalence or spectrum of disease present in a screening situation. The sensitivity and specificity values calculated from these studies should not be generalized to actual clinical populations. Patients with any other clinically relevant abnormalities such as polyps have been excluded from many of the studies. The cutoff values have been determined post hoc by examining the data.
Impact on Health Outcomes
There were no studies directly assessing the health outcomes of these previously marketed fecal DNA tests, and no modelling studies estimating health outcomes based on their test characteristics.
Summary of Evidence
The evidence for use of stool DNA in patients being screened for colorectal cancer includes a number of studies comparing stool DNA analysis (in early stages of development) with colonoscopy, and one large population screening study comparing the final version of the stool DNA testing and fecal immunochemical testing (FIT), using colonoscopy as the reference standard. Relevant outcomes are overall survival, disease-specific survival, and test accuracy. The population screening study reported that stool DNA analysis has higher sensitivity and lower specificity than FIT. There are no studies directly assessing health outcomes such as overall survival or disease-specific survival. The test characteristics of stool DNA testing show the potential of the test to be an effective colorectal cancer screening test, but there is uncertainty regarding other aspects of the test. The screening interval for the test has not been firmly established, nor is there evidence regarding the adherence of the test at a recommended screening interval. Effective screening for CRC requires a screening program with established screening intervals and appropriate follow-up for positive tests. The evidence is insufficient to determine the effects of the technology on health outcomes.
Practice Guidelines and Position Statements
Several recommendations of specialty organizations regarding fecal DNA testing were based largely on the 2004 study by Imperiale et al summarized previously, and should be considered obsolete. This includes 2008 guidelines from the American Cancer Society, 2012 guidelines from the American College of Physicians, and 2008 guidelines from the American College of Gastroenterology.
National Comprehensive Cancer Network
The 2015 National Comprehensive Cancer Network guidelines for CRC reviewed the study of Cologuard by Imperiale et al, and do not currently recommend stool DNA testing as a primary screening modality.
U.S. Preventive Services Task Force Recommendations
The U.S. Preventive Services Task Force (USPSTF) published recommendations for CRC screening with fecal DNA testing in October 2008. USPSTF concluded evidence is insufficient to assess the benefits and harms of fecal DNA testing as screening modalities for CRC (trade I statement). They limited their evidence review to only one study, the previously summarized study by Imperiale et al.
Draft recommendations released by the USPTF in 2015 refer to fecal DNA testing as a “FIT-DNA” test and categorize the test as an alternative test, which may be useful in certain clinical situations, but has a less mature evidence base to evaluate the test. Their recommendation is based solely on the study of Cologuard by Imperiale et al.
Colorectal cancer (CRC), DNA analysis, stool samples, chromosomal instability (CIN) pathway, mutator pathway, microsatellite instability (MSI), Mismatch repair (MMR) system, K-RAS gene, APC gene, p53 gene, BAT-26, L-DNA, PreGen™, stool-based DNA test, and Hereditary Nonpolyposis Colon Cancer (HNPCC), ColoSure™, vimentin methylation, vimentin (hV) gene, ColoGuard, ColoVantage, methylated septin 9
Approved by Governing Bodies:
On August 12, 2014, Cologuard™ (Exact Sciences) was approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process as an automated fecal DNA testing product (P130017). Cologuard™ is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced adenoma and should be followed by diagnostic colonoscopy. Cologuard™ is indicated to screen adults of either sex, 50 years or older, who are at average risk for CRC. Cologuard™ is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.
Over the past several years, different stool DNA tests have been evaluated in studies and some have been marketed. One of these previously marketed tests, PreGen-Plus™, tests for 21 different mutations in thep53,APC, and K- ras genes; the BAT-26 MSI marker; and incorporates the DNA Integrity Assay (DIA®). PreGen-Plus™ has not been cleared by the U.S. Food and Drug Administration (FDA). On January 13, 2006, FDA sent correspondence to LabCorp indicating that PreGen-Plus™ may be subject to FDA regulation as a medical device. As a consequence, and as a result of the studies showing better performance of other tests, this test is no longer offered. Another previously marketed test is called ColoSure™ developed by OncoMethylome, which detects aberrant methylation of the vimentin (hV) gene. This test is offered as a laboratory-developed test, not subject to FDA regulation.
Coverage is subject to member’s specific benefits. Group specific policy will supersede this policy when applicable.
ITS: Covered if covered by the Participating Home Plan
FEP contracts: FEP does not consider investigational if FDA approved and will be reviewed for medical necessity.
81528 Oncology (colorectal) screening, quantitative real-time target and signal amplification of 10 DNA markers (KRAS mutations, promoter methylation of NDRG4 and BMP3) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result (Effective 01/01/2016)
G0464 Colorectal cancer screening; stool-based DNA and fecal occult hemoglobin (e.g., KRAS, ndrg4 and bmp3) (Effective 01/01/15)
There are no specific codes for this laboratory procedure. A series of molecular diagnostic codes (83890-83914) would likely be used. (Deleted 01/01/13)
81479 Unlisted molecular pathology procedure (Effective 1/1/13)
S3713 KRAS mutation analysis testing (Deleted 4/1/12)
S3890 DNA analysis, fecal, for colorectal cancer screening (Deleted effective 01/01/2016)
Agency for Healthcare Research and Quality (AHRQ). Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: A joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American college of Radiology. National Guideline Clearinghouse. www.ahrq.gov.
Ahlquist, David A., et al. Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay panel. Gastroenterology 2000; 119: 1219-1227.
Ahlquist, David A., et al. Stool screening for colorectal cancer: Evolution from occult blood to molecular markers, review article. Clinica Chimica Act 315 (2002); 157-168.
Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008; 149: 441-450.
Ahlquist DA, Taylor WR, Manoney DW et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol 2012; 10(3): 272-7.
Ahlquist DA, Zou H, Domanico M et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology 2012; 142(2): 248-5
Baek YH, Chang E, Kim YJ et al. Stool methylation-specific polymerase chain reaction assay for the detection of colorectal neoplasia in Korean patients. Dis Colon Rectum 2009; 52(8):1452-9.
Blue Cross Blue Shield Association. Technology Evaluation Center. Special Report: Fecal DNA Analysis for Colorectal Cancer Screening. September 18, 2014.
Blue Cross Blue Shield Association. Special report: Fecal DNA analysis for colon cancer screening. Technical Evaluation Criteria (TEC) Assessment Program, August 2006, Vol. 21, No. 6.
Chen WD, Han ZJ, Skoletsky J et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 2005; 97:1124-32.
Dong, S.M., et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. Journal of the National Cancer Institute, June 6, 2001, Vol. 93, No. 11, pp. 858-865.
Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population, N Engl J Med, December 2004; 351(26): 2704-14.
Itzkowitz SH, Jandorf L, Brand R, et al. Improved fecal DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol, January 2007; 5(1) 111-117.
Itzkowitz S, Brand R, Jandorf L, et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol, November 2008; 103(11): 2862-2870.
Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society task force on colorectal cancer, and the American College of Radiology. CA Cancer J Clin 2008; 58(3):130-160.
Li M, Chen WD, Papadopoulos N et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol 2009; 27(9):858-63.
Lidgard GP, Domanico MJ, Bruinsma JJ et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin Gastroenterol Hepatol 2013; 11(10):1313-8.
National Cancer Institute. Colorectal Cancer Screening (PDQ®). www.cancer.gov/cancertopics/pdq/screening/colorectal/healthprofessional.
National Guideline Clearinghouse: www.guidelines.gov.
National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Colorectal Cancer Screening, v 1:2014 Available online at: www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf.
Provenzale D, Jasperson K, Ahnen DJ, et al. Colorectal Cancer Screening, Version 1.2015. J Natl Compr Canc Netw. Aug 2015; 13(8):959-968.
Qaseem A, Denberg TD, Hopkins RH, Jr. et al. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med 2012; 156(5):378-86.
Rex DK, Johnson DA, Anderson JC et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009; 104(3):739-50.
Schroy PC III and Heeren TC. Patient perceptions of stool-based DNA testing for colorectal cancer screening. Am J Prev Med, February 2005; 28(2): 208-214.
Shah R, Jones E, Vidart V, et al. Biomarkers for early detection of colorectal cancer and polyps: systematic review. Cancer Epidemiol Biomarkers Prev. Sep 2014; 23(9):1712-1728.
Song K. Fecal DNA testing compared with conventional colorectal cancer screening methods: A decision analysis. Gastroenterology 2004; 126(5): 1270-1279.
Traverso, G., et al. Detection of APC Mutation for colorectal cancer (CRC) screening. New England Journal of Medicine 2002; 346; 311-20.
Traverso, G., et al. Detection of proximal colorectal cancers through analysis of fecal DNA. Lancet 2002; 359; 403-4.
U.S. Preventive Services Task Force. Draft Recommendation Statement: Colorectal Cancer Screening. 2015; www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement38/colorectal-cancer-screening2.
U.S. Preventive Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med 2008; 149: 627-637.
Whitlock EP, Lin JS, et al. Screening for colorectal cancer: A targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149: 638-658.
Woolf SH. Editorial: A smarter strategy? Reflections on fecal DNA screening for colorectal cancer. NEJM 2004; 351(26): 2755-2758.
Medical Policy Group, April 2003 (3)
Medical Policy Administration Committee, April 2003
Available for comment May 7-June 20, 2003
Medical Policy Group, March 2005 (1)
Medical Policy Group, September 2006 (1)
Medical Policy Group, September 2008 (1)
Medical Policy Group, September 2010 (1): Key Points updated, no policy statement change
Coding update, effective January 1, 2011(1): Added code 88363, December 2010
Medical Policy Group, December 2010 (1): No additional information to be added to Key Points, recently updated in September.
Medical Policy Group, November 2011 (1): Update to Description, Key Points and References; no change in policy statement
Medical Policy Group, December 2011 (3): Coding update effective January 2012-added code 81275
Medical Policy Group, January 2012 (1): Update to Key Words with addition of vimentin methylation and vimentin (hV) gene
Medical Policy Group, February 2012 (1): Deleted HCPCS S3713 effective 4/1/12
Medical Policy Group, December 2012 (3): 2013 Coding Update: Deleted 83890-83914, addition of 81403, 81405, 81479 and 81599
Medical Policy Panel, November 2012
Medical Policy Group, January 2013 (1): Updates to Description, Key Points and References; no change to policy statement
Medical Policy Panel, November 2013
Medical Policy Group, January 2014 (1): Update to Key Points and References; no change to policy statement
Medical Policy Group, March 2014 (1): Added new Key Words, cologuard, colovantage and methylated septin 9; added code 81401 to policy
Medical Policy Group, November 2014: 2015 Annual Coding Update – Wording changes to codes 81403, & 81405. Added HCPCS code G0464 to current coding.
Medical Policy Panel, November 2014
Medical Policy Group, February 2015 (3): Updates to Description, Key Points, Current Coding – removed incorrect codes, and References; no change to policy statement.
Medical Policy Group, November 2015: 2016 Annual Coding Update. Added new CPT code 81528 to current coding and moved CPT S3890 from current coding to previous coding.
Medical Policy Panel, November 2015
Medical Policy Group, November 2015 (3): Updates to Key Points, Approved by Governing Bodies and References; no change to policy statement.
Medical Policy Group, November 2015: 2016 Coding Annual Update. Moved 81479 to previous coding.
Medical Policy Group, October 2017 (3): This policy is no longer effective as of Nov 1, 2017. Must refer to member benefits for coverage.
This medical policy is not an authorization, certification, explanation of benefits, or a contract. Eligibility and benefits are determined on a case-by-case basis according to the terms of the member’s plan in effect as of the date services are rendered. All medical policies are based on (i) research of current medical literature and (ii) review of common medical practices in the treatment and diagnosis of disease as of the date hereof. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment.
This policy is intended to be used for adjudication of claims (including pre-admission certification, pre-determinations, and pre-procedure review) in Blue Cross and Blue Shield’s administration of plan contracts.
The plan does not approve or deny procedures, services, testing, or equipment for our members. Our decisions concern coverage only. The decision of whether or not to have a certain test, treatment or procedure is one made between the physician and his/her patient. The plan administers benefits based on the member’s contract and corporate medical policies. Physicians should always exercise their best medical judgment in providing the care they feel is most appropriate for their patients. Needed care should not be delayed or refused because of a coverage determination.
As a general rule, benefits are payable under health plans only in cases of medical necessity and only if services or supplies are not investigational, provided the customer group contracts have such coverage.
The following Association Technology Evaluation Criteria must be met for a service/supply to be considered for coverage:
1. The technology must have final approval from the appropriate government regulatory bodies;
2. The scientific evidence must permit conclusions concerning the effect of the technology on health outcomes;
3. The technology must improve the net health outcome;
4. The technology must be as beneficial as any established alternatives;
5. The improvement must be attainable outside the investigational setting.
Medical Necessity means that health care services (e.g., procedures, treatments, supplies, devices, equipment, facilities or drugs) that a physician, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury or disease or its symptoms, and that are:
1. In accordance with generally accepted standards of medical practice; and
2. Clinically appropriate in terms of type, frequency, extent, site and duration and considered effective for the
patient’s illness, injury or disease; and
3. Not primarily for the convenience of the patient, physician or other health care provider; and
4. Not more costly than an alternative service or sequence of services at least as likely to produce equivalent
therapeutic or diagnostic results as to the diagnosis or treatment of that patient’s illness, injury or disease.